A phase III randomized double-blind placebo-controlled parallel-group multicenter efficacy and safety study of gantenerumab in patients with mild Alzheimer?s disease
M
Martin Farlow, MD
Primary Investigator
J
Jessica MacLean
Primary Investigator
Overview
In this study, we are hoping to learn about the effects, good or bad, of ?gantenerumab? compared with a ?dummy? drug (also called placebo).
Description
In this study, we are hoping to learn about the effects, good or bad, of ?gantenerumab? compared with a ?dummy? drug (also called placebo).
Eligibility
You may be eligible for this study if you meet the following criteria:
-
Conditions:
Alzheimer's Disease
-
Age: Between 50 Years - 90 Years
-
Gender: All
Updated on
26 Apr 2024.
Study ID: 1402739624
